GlassScriptPhysician profile
James Crumb
NPI 1265971097
$10,549.73
in general payments reported to CMS, 2019-2025
42 companies · $1,786 in 2025
The $1,786 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,906 · 2022: $2,358 · 2023: $2,451 · 2024: $2,049 · 2025: $1,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,285.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,146.58 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $1,227.74 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,050.83 | 2021-2025 | |
| Abbvie INC. | $1,010.63 | 2021-2025 | |
| Amgen INC. | $803.11 | 2021-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $739.47 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $497.51 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $467.95 | 2021-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $332.48 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Amarin Pharma, INC. | $233.98 | 2021-2022 | |
| Esperion Therapeutics, INC. | $191.58 | 2021-2022 | |
| Dexcom, INC. | $190.93 | 2021-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $182.60 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.82 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $162.22 | 2024-2025 | Veozah |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Crumb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.